To require the Food and Drug Administration to expedite review of pharmaceuticals that are approved for marketing in the European Union.

USA115^th CongressHR-2113| House

| Updated: 4/21/2017

Speeding Access to Already Approved Pharmaceuticals Act of 2017 This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration to facilitate the development and expedite the review of a new drug, biological product, or medical device that has been approved in the European Union.

View Full Text

Health

Administrative law and regulatory proceduresDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationEuropeEuropean UnionFood and Drug Administration (FDA)Prescription drugs

To require the Food and Drug Administration to expedite review of pharmaceuticals that are approved for marketing in the European Union.

USA115^th CongressHR-2113| House

| Updated: 4/21/2017

View Full Text

Steve Stivers

Republican Representative

Ohio

Cosponsors (2)

Tim Ryan (Democratic)Don Bacon (Republican)

Health Subcommittee, Energy and Commerce Committee

Health

Introduced
In Committee
On Floor
Passed Chamber
Enacted

To require the Food and Drug Administration to expedite review of pharmaceuticals that are approved for marketing in the European Union.

Suggested Questions

Health

To require the Food and Drug Administration to expedite review of pharmaceuticals that are approved for marketing in the European Union.

Suggested Questions

Steve Stivers

Health Subcommittee, Energy and Commerce Committee

Health

To require the Food and Drug Administration to expedite review of pharmaceuticals that are approved for marketing in the European Union.

Suggested Questions

Health

To require the Food and Drug Administration to expedite review of pharmaceuticals that are approved for marketing in the European Union.

Suggested Questions

Steve Stivers

Health Subcommittee, Energy and Commerce Committee

Health